Stockwinners Market Radar for March 07, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:06 EST Moelis exec Mahmoodzadegan sells 23,323 class A shares - In a regulatory filing, Moelis & Co. co-president, MD, Navid Mahmoodzadegan disclosed the sale of 23,323 class A common shares of the company on March 3 at a price of $43.05 per share.

19:44 EST Ellington Residential estimates book value per share of $8.56 as of February 28 - Ellington Residential Mortgage REIT announced its estimated book value per share of $8.56 as of February 28, 2023, which reflects a year-to-date total economic return of approximately 3.8% through February 28, 2023. This corrects the company's commentary on its earnings call earlier today, where it estimated its book value per share, as opposed to its year-to-date total economic return, as having increased close to 4% through February 28, 2023.

18:56 EST Akanda names Shailesh Bhushan as CFO - Akanda reported that it has appointed a new CFO. Effective immediately Shailesh Bhushan will join the company, and comes to Akanda with more than 25 years of financial and accounting experience. Bhushan's experience includes Chief Accounting Officer roles for Halo Collective and Namaste Technologies and accounting experience with Transact Network and Golden Leaf Holdings.

18:25 EST Pembina Pipeline announces renewal of share repurchase plan - Pembina Pipeline announced that the Toronto Stock Exchange has approved the renewal of Pembina's normal course issuer bid to purchase up to 5% of its issued and outstanding common shares.

17:39 EST Casey's General Stores narrows FY23 same-store inside sales view to up 6%-7% - The previous same-store inside sales outlook was up 5%-7%. The Company sees FY23 same-store fuel gallons to be down 1% to up 1% from previous guidance from flat to 2% higher. The Company is not updating its outlook for the following metrics. Inside margin is expected to be approximately 40%. Total operating expense increase, excluding the one-time benefit received this quarter, is expected to be near the low end of the annual range of approximately 9%-10%. The Company expects to add approximately 80 stores in FY23, and expects to exceed our stated three year commitment of 345 units. Interest expense is expected to be approximately $55M. Depreciation and amortization is expected to be approximately $320M and the purchase of property plant and equipment is expected to be approximately $450M-$500M, including approximately $135M in one-time store remodel costs for recently acquired stores. The tax rate is expected to be between approximately 24%-25% for the year.

17:34 EST Norfolk Southern CEO says cause of conductor accident 'not yet known' - Norfolk Southern provided a statement from president and CEO Alan H. Shaw: "As has now been widely reported, one of our Norfolk Southern colleagues was fatally injured overnight in a tragic accident on the job. Louis Shuster, a conductor from Broadview Heights, Ohio, was struck by a dump truck as his train moved through a rail crossing at the Cleveland-Cliffs Cleveland Works facility. I went to Cleveland as soon as I heard the tragic news. At our Rockport Yard, I talked with several railroaders who worked with Lou, as he was known. They shared stories about an individual who was respected and liked by his colleagues. This is an awful day that leaves a hole in our company's spirit. We have reached out to Lou's family to offer our condolences. We will give them time to grieve, and we will be there with support for anything they need. The cause of the accident is not yet known, and we will of course cooperate fully with the National Transportation Safety Board. In some ways, the cause does not matter. I called together every member of our management team this afternoon to emphasize the urgency of finding new solutions. Tomorrow we will hold safety stand-down briefings reaching every employee across our network. Moving forward, we are going to rebuild our safety culture from the ground up. We are going to invest more in safety. This is not who we are, it is not acceptable, and it will not continue."

17:17 EST Sensei Biotherapeutics adopts a limited duration stockholder rights agreement - Sensei Biotherapeutics announced that a special committee of the Board of Directors adopted a limited duration stockholder rights agreement to protect stockholder interests and maximize value for all stockholders. The Rights Agreement is intended to reduce the likelihood that any entity, person or group is able to gain control of Sensei through open market accumulation without paying all stockholders an appropriate control premium or providing the Board sufficient opportunity to make informed judgments and take actions that are in the best interests of all stockholders. Pursuant to the Rights Agreement, Sensei will issue, by means of a dividend, one preferred share purchase right for each outstanding share of Sensei common stock to stockholders of record on the close of business on March 17. Initially, these rights will not be exercisable and will trade with, and be represented by, the shares of Sensei common stock. The Rights Agreement will expire on March 7, 2024, or earlier, as provided in the Rights Agreement. Sensei remains committed to engaging in constructive dialogue with its stockholders, and the rights plan is not intended to prevent or interfere with any action with respect to Sensei that the Board determines to be in the best interests of the Company and its stockholders. Instead, it will position the Board to fulfill its fiduciary duties on behalf of all stockholders by ensuring that the Board has sufficient time to make informed judgments about any attempts to control or significantly influence Sensei. Jefferies is serving as financial advisor to Sensei and Sidley Austin LLP is serving as Sensei's legal advisor.

16:51 EST Senators introduce bipartisan bill to boost US ability to ban TikTok - U.S. Sens. Mark R. Warner D-VA , Chairman of the Senate Select Committee on Intelligence, and John Thune R-SD , ranking member of the Commerce Committee's Subcommittee on Communications, Media and Broadband, led a group of 12 bipartisan senators to introduce the Restricting the Emergence of Security Threats that Risk Information and Communications Technology or RESTRICT Act, legislation that will comprehensively address the ongoing threat posed by technology from foreign adversaries by better empowering the Department of Commerce to review, prevent, and mitigate information communications and technology transactions that pose undue risk to our national security. "Today, the threat that everyone is talking about is TikTok, and how it could enable surveillance by the Chinese Communist Party, or facilitate the spread of malign influence campaigns in the U.S. Before TikTok, however, it was Huawei and ZTE, which threatened our nation's telecommunications networks. And before that, it was Russia's Kaspersky Lab, which threatened the security of government and corporate devices," said Sen. Warner. "We need a comprehensive, risk-based approach that proactively tackles sources of potentially dangerous technology before they gain a foothold in America, so we aren't playing Whac-A-Mole and scrambling to catch up once they're already ubiquitous." "Congress needs to stop taking a piecemeal approach when it comes to technology from adversarial nations that pose national security risks," said Sen. Thune. "Our country needs a process in place to address these risks, which is why I'm pleased to work with Senator Warner to establish a holistic, methodical approach to address the threats posed by technology platforms - like TikTok - from foreign adversaries. This bipartisan legislation would take a necessary step to ensure consumers' information and our communications technology infrastructure is secure." The RESTRICT Act establishes a risk-based process, tailored to the rapidly changing technology and threat environment, by directing the Department of Commerce to identify and mitigate foreign threats to information and communications technology products and services. Other publicly traded companies in the social space include Meta Platforms (META), Pinterest (PINS), Snap (SNAP) and Alphabet (GOOG, GOOGL). Reference Link

16:37 EST Kewaunee Scientific subsidiary awarded contract for laboratory furniture - Kewaunee Scientific announced that the company's Indian subsidiary has been awarded a contract for laboratory furniture and technical products, delivered on a turnkey basis for Indian Oil Corporation, or IOCL, new green field research and development facility, located in Faridabad, India. The project was awarded by the project general contractor, Shapoorji Pallonji Ltd.

16:34 EST Asur reports February total passenger traffic up 23.9% vs. a year ago - Grupo Aeroportuario del Sureste announced that passenger traffic for February 2023 reached a total of 5.5M passengers, 23.9% above the levels reported in February 2022. Passenger traffic increased year-on-year by 25.6% in Mexico, 21.7% in Colombia and 20.5% in Puerto Rico. The growth of passenger traffic in Mexico, Colombia and Puerto Rico was mainly driven by increases in domestic traffic of 29.3%, 16.8% and 18.1%, respectively and in international traffic of 22.9%, 51.3% and 50.3%, respectively.

16:32 EST Bit Digital, Mega Matrix establish joint venture - Mega Matrix Corp. announced that its wholly-owned Singapore subsidiary, Saving Digital Pte. Ltd. has formed a joint venture with Bit Digital, Inc. by entering into a shareholders' agreement with MarsProtocol Technologies Pte. Ltd., the joint venture company, to jointly provide proof-of-stake technology tools for digital assets through the staking platform "MarsProtocol", an institutional grade non-custodial staking technology. The JV Company will be domiciled in Singapore. Before offering any services, the JV Company will undertake a regulatory review to ensure that its services are fully compliant with the laws of Singapore and any other nation in which it seeks to conduct business. Pursuant to the Agreement, Saving will control 60% of the Joint Venture. Bit Digital is a sustainability-focused generator of digital assets with large-scale bitcoin mining operations. Bit Digital is headquartered in New York with operations throughout North America. As of December 20, Bit Digital had 7,904 ETH and 2,004 sETH-h with a combined worth of approximately $12.1 million. 2,164 ETH were actively staked as of that date, using either native staking or liquid staking protocols. Bit Digital intends to continue accumulating Ethereum and stake substantially all of its ETH position over time.

16:31 EST Reed's CFO Tom Spisak resigns, Joann Tinnelly named interim CFO - Reed's announced that Tom Spisak has tendered his resignation as CFO of the company, effective March 30. Tom, who joined Reed's in December 2019, will continue to be available as a resource to ensure a smooth transition. Joann Tinnelly, current Vice President, Corporate Controller, who joined the company in 2018, will be appointed interim CFO until a permanent replacement is identified. Tinnelly brings more than 30 years of finance and accounting experience in global public and private equity company environments.

16:26 EST SVF Investment Corp. 2 will not consummate initial business combination - SVF Investment Corp. 2 announced that as of the close of business on March 9, the Company's publicly held Class A ordinary shares, par value 00.01c will be deemed cancelled and will represent only the right to receive their pro-rata share in the Company's trust account because the Company will not consummate an initial business combination within the time period required by its Amended and Restated Memorandum and Articles of Association. As stated in the Company's Articles and in the Company's registration statement on Form S-1, if the Company is unable to complete an initial business combination within 24 months of the initial public offering, the Company will: cease all operations except for the purpose of winding up, as promptly as reasonably possible but not more than ten business days thereafter, redeem the Public Shares, at a per-share price, payable in cash, equal to the aggregate amount then on deposit in the Trust Account, including interest earned on the funds held in the Trust Account and not previously released to the Company to pay its regulatory compliance costs and/or income taxes, if any, divided by the number of the then-outstanding Public Shares, which redemption will completely extinguish public shareholders' rights as shareholders; and as promptly as reasonably possible following such redemption, subject to the approval of the Company's remaining shareholders and the Company's board of directors, liquidate and dissolve, subject in each case to the Company's obligations under Cayman Islands law to provide for claims of creditors and the requirements of other applicable law. The per-share redemption price for the Public Shares will be approximately $10.21. The balance of the Trust Account as of March 3 was approximately $235,033,747, which includes $5,033,747 in interest and dividend income. In accordance with the terms of the related trust agreement, the Company expects to retain $100,000 of the interest and dividend income from the Trust Account to pay dissolution expenses. As of the close of business on March 9, the Public Shares will be deemed cancelled and will represent only the right to receive the Redemption Amount on or around March 23. The Company anticipates that the Public Shares will cease trading on The Nasdaq Capital Market as of the close of business on March 9. The Redemption Amount will be payable to the holders of the Public Shares upon delivery of their shares to the Company's transfer agent, Continental Stock Transfer & Trust Company. Beneficial owners of Public Shares held in "street name," however, will not need to take any action in order to receive the Redemption Amount. The Company's sponsor has agreed to waive its redemption rights with respect to its outstanding Class B ordinary shares issued prior to the Company's initial public offering. There will be no redemption rights or liquidating distributions with respect to the Company's warrants, which will expire worthless. After March 9 the Company shall cease all operations except for those required to wind up the Company's business. The Company expects that Nasdaq will file a Form 25 with the Commission in order to delist the Company's securities.

16:18 EST PayPal reports Blake Jorgensen stepping down as CFO - Effective March 7, Blake Jorgensen will step down from his position as Chief Financial Officer of PayPal Holdings, following a leave of absence for health reasons that started in September, the company announced. Jorgensen will remain with the company as a senior advisor through September 15. At the start of Blake's leave of absence in September 2022, Gabrielle Rabinovitch was named acting Chief Financial Officer and she will continue in that role, PayPal stated. Reference Link

16:16 EST Banner Acquisition announces letters of intent for business combination - Banner Acquisition Corp. announced its intent to create, via business combination with multiple targets, a new publicly traded platform focused on the property services sector. Banner has entered into multiple letters of intent with target companies in the sector and intends to continue seeking additional acquisition targets that provide services in areas such as cleaning, HVAC, plumbing, landscaping, pest control, residential solar and energy management, restoration, facility management and other related businesses. As a result of the signed letters of intent, pursuant to the provisions of Banner's Amended and Restated Certificate of Incorporation, Banner has until June 10, 2023 to consummate its business combination. The letters of intent are non-binding with respect to all material terms, except with respect to certain customary provisions. There can be no assurance that the parties will enter into definitive agreements or that the parties will consummate the transactions on the terms or timeframe currently contemplated, or at all. If Banner does not consummate a business combination on or before June 10, 2023, and Banner's stockholders have not approved an extension of the combination period by amending the Charter, there will be a mandatory liquidation and subsequent dissolution of Banner.

16:15 EST Sumo Logic withdraws previous financial guidance due to pending transaction - In a separate press release issued on February 9, Sumo Logic announced that it has entered into a definitive agreement to be acquired by entities affiliated with Francisco Partners Management. A copy of the press release and supplemental materials can be found on the investor relations page of Sumo Logic's website at investors.sumologic.com. The additional details and information about the terms and conditions of the definitive agreement and the transactions are available in the Current Report on Form 8-K filed by Sumo Logic with the Securities and Exchange Commission on February 9, .Given the announced transaction, Sumo Logic will not host an earnings conference call or provide financial guidance in conjunction with this earnings release. Sumo Logic is also withdrawing its previous financial guidance as a result of the pending transaction. For further detail and discussion of Sumo Logic's financial performance please refer to Sumo Logic's Annual Report on Form 10-K for the quarter and fiscal year ended January 31 , which will be filed subsequently with the SEC.

16:13 EST BioMarin: FDA accepts sNDA to expand use of VOXZOGO for injection - BioMarin Pharmaceutical announced that the U.S. FDA has accepted the company's supplemental New Drug Application for VOXZOGO for injection to expand treatment in the United States to include children with achondroplasia under the age of 5. Achondroplasia is the most common form of disproportionate short stature. The FDA has set a PDUFA target action date of October 21, 2023 for the sNDA.

16:10 EST Fresh Tracks announces results for dose parts of FRTX-02 study - Fresh Tracks Therapeutics announced positive topline results from the single ascending dose and multiple ascending dose parts of its Phase 1 clinical trial evaluating FRTX-02 in healthy subjects. FRTX-02 is a potent, highly selective, and orally bioavailable potential first-in-class DYRK1A inhibitor that aims to restore immune balance by modulating both adaptive and innate immune responses in patients with autoimmune and inflammatory diseases. In parallel, the Company's Board of Directors approved a comprehensive process to explore and evaluate strategic options to progress the development of its novel pipeline to maximize shareholder value."The results from Part 1 of the first-in-human Phase 1 study demonstrate the potential of FRTX-02 as a generally safe and well-tolerated, once-daily oral treatment for a broad range of autoimmune and inflammatory diseases," commented Andy Sklawer, President and Chief Executive Officer of Fresh Tracks. "This clinical trial marks the first time an oral DYRK1A inhibitor intended for patients with autoimmune diseases has entered the clinic, and these topline SAD and MAD data reinforce our enthusiasm for the continued development of FRTX-02 as a potential first-in-class therapy. However, to fully unlock the potential of the Company's pipeline considering our current capital resources, we have determined it is prudent for us to initiate a comprehensive review of strategic options with the goal of maximizing shareholder value as we look to advance the clinical development of FRTX-02 and progress our earlier-stage assets." Dr. Bernard Khor, MD, PhD, Principal Investigator and Assistant Member at the Benaroya Research Institute for Translational Medicine and Affiliated Assistant Professor at the University of Washington, added, "I am encouraged by the results from the FRTX-02 Phase 1 SAD and MAD clinical study. These safety, pharmacokinetics and exploratory pharmacodynamics ("PD") data expand our understanding of DYRK1A's potential as a promising, novel target with potential clinical utility that could have disease modifying effects in autoimmunity and inflammation. Furthermore, the results from this trial mark an important step forward for inhibition of the historically undruggable DYRK1A target and highlight the potential of FRTX-02 as a first-in-class, once-daily oral autoimmune therapy. I look forward to participating in the continued development of FRTX-02."

16:05 EST Sun Country Airlines appoints Jennifer Vogel chair of board - Sun Country Airlines has appointed Jennifer L. Vogel as chair of the board of directors, effective March 7. Vogel, former senior vice president, general counsel, secretary and chief compliance officer of Continental Airlines ., joined the board in October 2022. Vogel has extensive board governance and executive leadership experience. She has served on multiple public company boards, overseeing major transactions, and leading the development of best practices in corporate governance, crisis and enterprise risk management, executive compensation, and corporate compliance. At Continental, she played key roles in helping the airline achieve substantial global expansion, including the merger of Continental Airlines with United Airlines. She serves on the board of AAR Corp, and previously served on the boards of Virgin America Inc., American Science and Engineering, Inc., and Clearwire Corporation. She has been recognized as one of the "Most Influential Corporate Board Directors" by Women's Inc., "Most Powerful and Influential Women in Texas" by the Texas Diversity Council and Texas Diversity Magazine.

16:04 EST Marinus sees FY23 ZTALMY U.S. net product revenue $15M-$17M - For the fiscal year 2023, the company expects ZTALMY U.S. net product revenues of between $15 million and $17 million, BARDA revenues in the range of $8 million to $11 million and total GAAP operating expenses, inclusive of SG&A and R&D, to be in the range of $165 to $175 million, of which the company expects stock-based compensation to be approximately $16 million.

13:14 EST CP announces ratification of new collective agreement with BLET in Midwest - Canadian Pacific announced the ratification of a new collective agreement with the Brotherhood of Locomotive Engineers and Trainmen, or BLET, representing hundreds of CP and Kansas City Southern locomotive engineers and trainmen in U.S. Midwest locations, which will take effect upon the consummation of the proposed CP-KCS combination, which remains subject to receipt of regulatory approval by the U.S. Surface Transportation Board. CP's proposed combination with KCS remains subject to regulatory approval by the STB. An STB decision is expected in first quarter of 2023. "These hourly agreements improve pay and quality of life for our employees by providing more scheduled time off, something national agreements typically don't, while creating the operational flexibility needed to deliver better service to our customers. These innovative agreements will create predictable schedules for conductors and engineers and empower us to attract and retain the most talented railroaders in the industry as we successfully serve our customers with, pending regulatory approval, a combined CPKC connecting Canada, the U.S. and Mexico," said Keith Creel, CP President and CEO.

12:58 EST JetBlue, Spirit Airlines to 'vigorously defend' merger plan - JetBlue Airways (JBLU) and Spirit Airlines (SAVE) responded to the filing of a complaint by the U.S. Department of Justice seeking to block the companies' merger, stating: "JetBlue and Spirit will continue to advance our plan to create a compelling national challenger to the Big Four airlines, which control about 80% of the market after years of industry consolidation that the DOJ itself approved. By coming together, we will expand JetBlue's unique offering - where customers do not have to choose between a low fare and a great experience - to boost competition nationally. JetBlue has proven its ability to force the legacy carriers to react to JetBlue's low fares and award-winning service. The DOJ itself said that 'In the face of consolidation, JetBlue has provided an important and steadfast source of competition' and that 'JetBlue's reputation for lowering fares is so well known in the airline industry that it has earned a name: the 'JetBlue Effect.'" JetBlue CEO Robin Hayes said: "Customers deserve a competitive airline marketplace and we will pursue this merger to ensure they get it, continuing to disrupt the legacy airlines with low fares and award-winning service that even the DOJ has applauded. We believe the DOJ has got it wrong on the law here and misses the point that this merger will create a national low-fare, high-quality competitor to the Big Four carriers which - thanks to their own DOJ-approved mergers - control about 80% of the U.S. market. There is too much at stake for the DOJ to prevent us from bringing the JetBlue difference to more customers in more markets." Spirit CEO Ted Christie said: "We disagree with the DOJ's decision to seek to block the proposed merger, which will benefit consumers and employees. We will vigorously defend our position that a combined JetBlue and Spirit will be a game changer for customers nationwide, creating the most compelling national low-fare challenger to the dominant U.S. carriers. Together, we intend to democratize flying for travelers across the country - a goal we believe is worthy of the government's support."

12:04 EST Precipio signs additional HemeScreen customer - Precipio continues to convert its sales pipeline into HemeScreen customers, with an additional recently signed agreement expected to generate annualized revenues exceeding $125,000.

12:01 EST Siemens Mobility to inves $220M into North Carolina rail manufacturing facility - Siemens Mobility will expand its manufacturing footprint by building a $220M advanced manufacturing and rail services facility in Lexington, NC. The facility will create more than 500 new jobs and be one of the city's largest employers. With the increased production capacity, Siemens Mobility will fulfill the growing demand for passenger rail in America by producing some of the most innovative and sustainable passenger trains in the North American market. Because of the Biden Administration, North Carolina's Congressional Delegation, and other congressional stakeholders, the Bipartisan Infrastructure Law is enabling American rail and transit operators to make critically needed investments in infrastructure that will position the country to meet the needs of its citizens with rail networks designed for future generations.

12:00 EST Aris Water Solutions falls -17.3% - Aris Water Solutions is down -17.3%, or -$2.29 to $10.95.

12:00 EST Squarespace rises 11.3% - Squarespace is up 11.3%, or $2.71 to $26.75.

12:00 EST Sea Limited rises 18.6% - Sea Limited is up 18.6%, or $12.20 to $77.91.

11:08 EST Verizon maintaining outlook for 2023 provided in January, says CFO - CFO Matt Ellis says the consumer is in "good shape overall." Comments taken from the Morgan Stanley Technology, Media & Telecom Conference 2023.

11:04 EST Ferguson under pressure following quarterly results, guidance - Shares of Ferguson are under pressure in Tuesday morning trading after the company reported quarterly results, with Q2 net income declining to $374M from $436M the year prior. The company also reported Q2 earnings per share from continuing operations of $1.80 versus $1.97 year-over-year, with Q2 adjusted EPS at $1.91. Ferguson's net sales for the quarter came in at $6.8B, up 4.9% year-over-year. For 2023, the company sees net sales of low single digit growth and adjusted operating margin of 9.3%-9.9%. Additionally, Ferguson also declared quarterly dividend of 75c. PRICE ACTION: Shares of Ferguson have dropped over 3% to $138.76 in Tuesday morning trading.

11:02 EST Lockheed Martin, Korea Aerospace, Red 6 enter emerging technology partnership - Lockheed Martin, Korea Aerospace Industries and Red 6 Aerospace announced a new partnership that will deliver advanced 21st Century Security capabilities across a spectrum of training and combat aircraft. The partnership will initially bring Red 6's revolutionary augmented reality platform, the Airborne Tactical Augmented Reality System, into the TF-50 and variants. The system gives pilots and ground operators new capabilities to see and interact with synthetic threats in real-time, high-speed environments. Lockheed Martin recently submitted the TF-50A variant in response to the U.S. Air Force's February 2023 request for information for a two-seater aircraft to cover three near-term missions including tactical training, adversarial air support and to serve as a tactical fighter surrogate. The TF-50A is configured as a light attack fighter/trainer with additional enhancements to include radar, electronic warfare system, tactical data link, and other capabilities to meet Air Combat Command requirements. While the ATARS system is initially targeted for the TF-50 and variants, it could eventually be applied to operational Lockheed Martin platforms such as the F-16, F-22 and F-35.

10:39 EST DOJ files suit opposing proposed JetBlue acquisition of Spirit Airlines - In a complaint filed in the U.S. District Court for the District of Massachusetts, the Department of Justice is joined by the state of Massachusetts, the state of New York and the District of Columbia in alleging "JetBlue's proposed $3.8 billion acquisition of Spirit would eliminate the largest and fastest-growing ultra-low-cost carrier in the United States." The suit states in part: "JetBlue competes hard against Spirit, and views it as a serious competitive threat. But instead of continuing that competition, JetBlue now proposes an acquisition [that if approved,] JetBlue plans to abandon Spirit's business model, remove seats from Spirit's planes, and charge Spirit's customers higher prices. JetBlue's plan would eliminate the unique competition that Spirit provides-and about half of all ultra-low-cost airline seats in the industry-and leave tens of millions of travelers to face higher fares and fewer options... This acquisition violates Section 7 of the Clayton Act and should be enjoined."

10:10 EST HPX Corp trading halted, volatility trading pause

10:01 EST HII receives additive manufacturing approval from Naval Sea Systems Command - HII announced that its Newport News Shipbuilding division recently received approval as a vendor to provide some additive manufacturing components to Naval Sea Systems platforms. The certification enables NNS to use additive manufacturing, or 3D printing, to fabricate pipefittings or other potential components for use on aircraft carriers, submarines and other NAVSEA platforms.

10:00 EST Ambrx Biopharma falls -13.4% - Ambrx Biopharma is down -13.4%, or -$1.69 to $10.86.

10:00 EST Enfusion rises 11.4% - Enfusion is up 11.4%, or $1.16 to $11.27.

10:00 EST Quotient Technology rises 17.2% - Quotient Technology is up 17.2%, or 57c to $3.89.

09:47 EST Grindr falls -10.6% - Grindr is down -10.6%, or -76c to $6.45.

09:47 EST Aris Water Solutions falls -12.4% - Aris Water Solutions is down -12.4%, or -$1.64 to $11.60.

09:47 EST Squarespace rises 7.2% - Squarespace is up 7.2%, or $1.73 to $25.77.

09:46 EST Quotient jumps 7% to $3.54 after Reuters says exploring sale

09:40 EST Goldman Sachs CEO: U.S. economy has proved to be more resilient - Chairman and CEO David Solomon said the Fed "seems to be doing a good job."

09:33 EST BetMGM becomes official sports betting partner of Boston Red Sox - BetMGM is now an Official Sports Betting Partner of the Boston Red Sox. This marks BetMGM's first relationship with a Massachusetts sports team and the first sports betting partnership for the Red Sox. The announcement comes ahead of the state's impending mobile sports betting launch. As part of the partnership, BetMGM signage will be featured at Fenway Park including on the iconic Green Monster, the ballpark's left field wall. BetMGM will have a suite at the stadium and curate VIP fan experiences including access to batting practice with premium seats, alumni appearances, and ceremonial first pitches. Co-branded content will be integrated across both the Red Sox's and BetMGM's digital and social platforms.

09:25 EST SentinelOne enters exclusive partnership with Wiz - SentinelOne announced an exclusive and strategic partnership with Wiz. Through the strategic partnership, the combined expertise of Wiz's Cloud Native Application Protection Platform, or CNAPP, and SentinelOne's Cloud Workload Protection Platform, or CWPP, can be offered to organizations of all sizes and equip customers with a cloud security solution that provides superior capabilities to detect, prevent, investigate, and respond to cloud security threats, allowing them to dramatically reduce their risk.

09:24 EST Goldman Sachs CEO: Banking, markets business outperformed rivals - Chairman and CEO David Solomon is speaking at the RBC Global Financial Institutions Conference.

09:21 EST ZyVersa appoints Richard Glassock to Renal Scientific Advisory Board - ZyVersa Therapeutics announces that Dr. Richard Glassock has joined ZyVersa's Renal Scientific Advisory Board. Glassock is currently Professor Emeritus at the David Geffen School of Medicine at UCLA, and an independent medical consultant. His main interests are in glomerular disease, chronic kidney disease, and clinical nephrology

09:20 EST Aclarion appoints Alpesh Patel as KOL physician advisor - Aclarion announced that Alpesh Patel, MD, MBA Co-Director of Northwestern Center for Spine Health will advise the company as a key opinion leader. In addition to his leadership role in the Center for Spine Health, Dr. Patel serves as professor of Orthopaedic Surgery and Neurosurgery at Northwestern University in Evanston, IL.

09:19 EST Tyler Technologies renews digital government, payment solutions in Colorado - Tyler Technologies announced that the Colorado Statewide Internet Portal Authority, or SIPA, on behalf of the state of Colorado, has signed a contract renewal for Tyler's award-winning digital government and payments services, following a competitive procurement. The five-year contract renewal, which may be extended for up to five additional years at the state's option, builds upon the existing 18-year relationship between Colorado's SIPA and Tyler's Digital Solutions Division, formerly NIC. The agreement features a new funding model that will streamline processes for agencies to implement and utilize Tyler's products and software-as-a-service solutions.

09:14 EST Black Knight to divest Empower Los business amid regulatory scrutiny - Intercontinental Exchange (ICE) and Black Knight (BKI) announced that, in connection with their previously announced merger agreement for ICE's acquisition of Black Knight, they have agreed to sell Black Knight's Empower loan origination system business, including its Exchange, LendingSpace and AIVA solutions, to a subsidiary of Constellation Software. ICE and Black Knight have also amended the terms of their merger agreement. ICE and Black Knight entered into the divestiture agreement in connection with efforts to secure clearance of ICE's proposed acquisition of Black Knight under the Hart-Scott Rodino Act. The divestiture transaction is subject to the closing of ICE's acquisition of Black Knight and other customary closing conditions. The amended merger agreement terms value Black Knight at $75 per share, or a market value of $11.7B, with consideration in the form of a mix of approximately $68 per share in cash and stock with an exchange ratio of 0.0682 based on ICE's 10-day VWAP as of March 3 of $102.62. As under the original terms, Black Knight shareholders can elect to receive either cash or stock, subject to proration, with the value of the cash election and the stock election equalized at the closing of the acquisition. ICE's proposed acquisition of Black Knight remains under review by the Federal Trade Commission and closing is subject to the receipt of required regulatory clearances, Black Knight shareholder approval of the amended merger agreement and the satisfaction of other customary closing conditions. In connection with the amendment to the merger agreement, ICE has committed to, among other things, litigate with the FTC, if necessary, to obtain approval of the merger. Truist Securities, Inc. served as lead financial advisor to Intercontinental Exchange and Black Knight for the sale of the Empower LOS.

09:12 EST Telus expands Health for Good program to support women in need across Canada - TELUS announced the expansion of its Health for Good program to now provide free access to TELUS Health MyCare counselling services to women in need of mental health support across Canada. TELUS Health MyCare offers direct access to counselling provided by caring, registered mental health professionals in British Columbia, Alberta, Saskatchewan, Ontario and Quebec. Partnering with three women-focused charities, TELUS will provide over 1,000 free counselling sessions per year to women in B.C., Alberta, Saskatchewan and Ontario. "The pandemic has taken a toll on mothers, family caregivers, women and gender diverse people," said Jill Schnarr, Chief Social Innovation and Communications Officer, TELUS. "As a world-leading technology company and a global health care leader, we are leveraging our technology, expertise and compassion for good. Helping more women through our TELUS Health for Good program, this expansion is focused on removing barriers, making it easier and more affordable to access mental health services and making a meaningful difference in their lives."

09:10 EST Catapult Group to launch Vector T7 athlete monitoring solution - Catapult will launch a new athlete monitoring solution, the Vector T7, on April 1. The device is 73% smaller than its predecessor and delivers the most accurate and comprehensive player data in indoor environments, including the company's proprietary "Basketball Movement Profile." Combined with Capapult's ClearSky Local Positioning System, the Vector T7 empowers teams to leverage new player performance insights, mitigate injury risk, and make live in-game decisions.

09:08 EST Rumble opens new studio for content creators in Florida - Rumble announced today the opening of a new creator studio in Longboat Key, Florida. The studio is freshly renovated as part of the construction of Rumble's U.S. headquarters in Longboat Key. This is the second creator studio hosted by Rumble in the state of Florida, following the opening of a studio by the company's subscription platform Locals in Miami in September 2022. "Supporting independent creators is a core tenant of the Rumble mission," said Rumble Chairman and CEO Chris Pavlovski. "Our goal is to provide a world-class experience for our creators so they can generate their best content," he continued. "This studio is hosted on the shores of Longboat Key, and I can say confidently that this is one of the most beautiful settings you will ever see for a creator studio."

09:07 EST F-star Therapeutics announces CFIUS clearance for proposed acquisition by invoX - F-star Therapeutics announced that the Committee on Foreign Investment in the United States has cleared the previously announced all-cash acquisition of the Company by invoX Pharma Limited. The CFIUS clearance satisfies the Foreign Investment Condition of the ongoing tender offer, and is the final required regulatory approval needed to complete the proposed merger. As described below, the parties expect to complete the merger promptly following the successful completion of the ongoing tender offer. Specifically, the Offer is scheduled to expire on March 8, 2023 at 5 p.m., Eastern Time. Subject to the tendering of shares of F-star common stock representing greater than 50% of the issued and outstanding shares and the satisfaction of customary conditions, the parties expect to complete the merger promptly following this tender expiry. Previously, shares of common stock representing nearly 70% of the issued and outstanding shares had been validly tendered as of the prior expiration dates.

09:06 EST Flowers Foods elects A. Ryals McMullian as the next chairman of the board - Flowers Foods announced that A. Ryals McMullian has been elected as the next chairman of the board, effective immediately following the 2023 annual meeting of shareholders. George Deese, current chairman of the board, will retire from the chairman role at that time. Deese will continue to serve as a director following the annual meeting of shareholders. Additionally, Benjamin H. Griswold, IV will retire from the company's board of directors following the expiration of his current term. Griswold, partner and chairman of Brown Advisory and retired Senior Chairman of Deutsche Bank Securities, has served as a director of Flowers Foods since 2005 and currently serves as presiding director, chair of the nominating/corporate governance committee and member of the compensation and human capital committee. The board has elected Thomas C. Chubb, III to serve as presiding director and chair of the nominating/corporate governance committee, effective immediately following the annual meeting of shareholders. Ryals McMullian has served as a member of Flowers Foods' board since August 2019 and was elected president and CEO of Flowers in May 2019. Prior to that election, he served in a number of senior leadership roles for the company, including chief operating officer, chief strategy officer, deputy general counsel, and vice president of mergers and acquisitions. He joined Flowers Foods in 2003. Tom Chubb, chairman, CEO and president of Oxford Industries, has served as a member of the Flowers Foods' board since 2020.

09:05 EST Tetra Tech wins $105M EPA watershed assessment and protection BPA - Tetra Tech announced that the U.S. Environmental Protection Agency, EPA, Office of Water awarded the Company a five-year, $105M Blanket Purchase Agreement, BPA, to restore and protect watersheds and water bodies throughout the United States. Tetra Tech will identify, analyze, and evaluate surface water and coastal ecosystems to protect human health and aquatic environments from the impacts of pollution and the effects of climate change, including ocean acidification. Tetra Tech's scientists will design monitoring programs, develop predictive models, and prepare technical guidance documents to assess chemical, physical, and biological integrity of water bodies. Our technical specialists will analyze model results and manage spatial datasets to develop effective management strategies for inland and coastal regions impacted by land-use related activities, stormwater and runoff, habitat loss, and invasive species.

09:04 EST Verisk Analytics announces $2.5B accelerated share repurchase transaction - Verisk Analytics (VRSK) announced that it has entered into accelerated share repurchase agreements, ASR agreements, with each of Citibank (C) and Goldman Sachs (GS) to repurchase an aggregate of $2.5 billion of the Company's common stock. The ASR Agreements were entered into as part of the Company's previously announced share repurchase program. The ASR Counterparties are expected to make an aggregate initial delivery of approximately 10.7 million shares of the Company's common stock to the Company at the inception of the ASR Agreements. The final settlement of the transactions under the ASR Agreements is expected to occur during the Company's fourth fiscal quarter ending December 31, 2023. Verisk may continue to repurchase shares in the open market from time to time subject to market and other conditions. After giving effect to the ASR Agreements, $941.3 million will remain available for share repurchases under the Company's authorized share repurchase program.

09:02 EST Abbott: FDA clears first first commercially available TBI blood test - Abbott has received U.S. FDA clearance for what will be the first commercially available laboratory traumatic brain injury blood test, making it widely available to hospitals in the United States. The test, which runs on Abbott's Alinity i laboratory instrument, will provide clinicians with an objective way to quickly assess individuals with mild TBIs, also known as concussions. Abbott's Alinity i TBI lab test offers a new reliable result in 18 minutes to help clinicians quickly assess concussion and triage patients. For those with negative results, it rules out the need for a CT scan and can eliminate wait time at the hospital. The test measures two biomarkers in the blood that, in elevated concentrations, are tightly correlated to brain injury.

08:45 EST Sypris Solutions awarded additional volume with Daimler Truck unit - Sypris Technologies (SYPR) announced that it has entered into an amendment to its current supply agreement with Detroit Diesel Corporation, DDC, a subsidiary of Daimler Truck North America (DTRUY). The amendment adds a new series of part numbers to its agreement with DDC for drivetrain components used in DDC's Detroit(R)-branded drive axles. The components produced by Sypris are essential to the performance of the drive axles of Freightliner's heavy-duty vehicles. Production of these additional part numbers under the amended contract are expected to commence in early 2023. No other terms or conditions of the agreement were disclosed. Commenting on the announcement, Federico Aviles, Vice President and General Manager of Sypris Technologies Mexico, S. de R.L. de C. V., stated, "We are pleased to expand our strategic relationship with Daimler Truck, which is now entering its 18th year. Daimler Truck is a global leader in the commercial vehicle industry and we are proud to serve as a partner by supplying quality products to support its reputation for high performance and durability."

08:42 EST BK Technologies receives $1.4M follow-on purchase order for BKR 5000 - BK Technologies has received a purchase order valued at $1.4M from the Washington State Department of Natural Resources for its BKR 5000 portable communications technology and accessories. This is the second significant purchase of the BKR 5000 by the DNR following an order valued at $1.4M placed in December 2022.

08:39 EST Biotricity highlights 2022 operating milestones - Biotricity highlighted several of its major operating achievements since fiscal year 2022. These achievements include: Being honored by TIME magazine: Biotricity's Bioheart device named to TIME's list of the Best Inventions of 2022. Bioheart is the first of its kind - a continuous heart rhythm monitor using advanced technology to deliver unlimited heart data insights. Bioheart's uninterrupted monitoring keeps you informed about your heart 24/7. Being recognized on Fast Company's list of the World's 50 Most Innovative Companies in 2022, and ranked No. 1 in the Top 10 Most Innovative Medical Device Companies. Launch of Biocare Cardiac Disease Management Solution: designed to expand Biotricity's existing remote monitoring tools used today by more than 2,000 cardiologists nationwide, the easy-to-use solution puts actionable data at the physicians' fingertips to assist them in making treatment decisions quickly. Releasing a personal version of Biocare Cardiac, a cardiac health application for individuals diagnosed with, or at risk for, cardiovascular disease for personal disease management. Winning an NIH Grant from the National Heart, Blood, and Lung Institute for AI-enabled real-time monitoring and predictive analytics for stroke due to chronic kidney failure. This grant is supporting development of Biotricity's Bioflux-AI - an innovative AI-driven system with real-time monitoring and prediction capabilities to be used to investigate stroke episodes in chronic kidney disease patients. Receiving 510 Clearance for Biotres and launching the wireless wearable holter patch device, Biotres. Unveiling Biokit, a personal medical device kit for integration into the Biotricity ecosystem. Expanding its network to 300+ centers across 30+ states with 2,000+ physicians. Realizing a significant milestone of recording and analyzing over 2 billion heartbeats for atrial fibrillation, the most common type of cardiac arrhythmia and a leading cause of stroke. Bioflux, Biotricity's high-precision, single-unit mobile cardiac telemetry device that provides real-time monitoring and transmission of the patient's ECG information, has captured billions of heartbeats to date.

08:35 EST Ault, Ecoark complete $100M share exchange agreement - Ault Alliance (AULT) and Ecoark Holdings (ZEST) announced today that they have completed the previously announced share exchange agreement, whereby Ault Alliance and other founders sold BitNile.com, Inc., including the BITNILE.COM metaverse platform, to Ecoark for $100 million in stated value of preferred stock. The Platform, which went live to the public on March 1, 2023, allows users to engage with a new social networking community and purchase both digital and physical products while playing 3D immersive games. The Platform is expected to have a tiered rewards system, which incentivizes behavior, while advertising models will target specific users. The Platform is early access and not all experiences are immediately available. Once Ecoark has obtained shareholder approval for the issuance of all the shares underlying the Ecoark preferred stock called for by the Agreement in compliance with the rules and regulations of Nasdaq, Ault Alliance will beneficially own a significant majority of Ecoark. Going forward, it is expected that Ecoark's financial results will be consolidated into Ault Alliance's financial statements. This acquisition is expected to bring synergies and opportunities for growth for both companies, as they work towards their shared goals in the metaverse market. The Preferred Stock has a stated value of $100 million, is convertible into shares of Ecoark common stock at $0.25 per share subject to Ecoark obtaining shareholder approval, accrue dividends of 5% per annum for 10 years, and the holders are entitled to certain other rights as set forth in the certificate of designation for the Preferred Stock. Subject to shareholder approval, Ault Alliance can vote and convert the majority of the Preferred Stock at its discretion. Until it obtains that approval, Ault Alliance is subject to a 19.9% limitation on an as converted basis in accordance with the Rules of the Nasdaq Stock Market, which percentage includes other Ecoark securities it presently holds.

08:34 EST Sellas Life announces publication of GPS clinical data in ovarian cancer - SELLAS Life Sciences announced that the previously reported results from the final analysis of a Phase 1 clinical trial of the combination of galinpepimut-S with the anti-PD-1 antibody nivolumab in patients with relapsed WT1-expressing ovarian cancers have been published in the peer-reviewed journal Cancers. The article entitled "Phase I Study of a Multivalent WT1 Peptide Vaccine in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third Remission" was published February 25, 2023 in "Advances in the Treatment of Ovarian Cancer," a special issue of the journal Cancers. Key Takeaways of Published Study Data: Broader than expected GPS immunologic responses encompassed both T-cells and antibodies. 91% of patients treated had definite WT1-specific T-cell responses post-therapy, while in 88% of evaluable patients there was emergence of immunoglobulins against both a pool of the GPS constituent WT1 peptides and full-length WT1 protein. Cellular and humoral robust antigen-specific immune responses translated into clear clinical benefit with 70% one-year progression-free survival demonstrated in patients who received two or more treatments of GPS and nivolumab as maintenance immunotherapy after salvage chemotherapy, compared to historic rates of up to 55% in comparable patient populations in the absence of any maintenance treatment. Data suggest that durable responses to maintenance GPS immunotherapy can be attained in patients with WT1-expressing ovarian cancer, thus delaying measurable disease relapse. These results also corroborate previously announced findings from the final analysis of data from a Phase 1/2 study.

08:33 EST GelStat forms GSAC Engineering division - GelStat launched a new engineering division called GSAC Engineering, marking a milestone in the Company's long-term turnaround plan to drive its corporate growth strategy. The Company's senior management team has been evaluating various market opportunities that could support a tangible growth path. In parallel to market research, GelStat has been developing technology and intellectual property to support this strategy. GSACe plans to initially focus on developing innovative technology for the industrial security and renewable energy markets. In particular, the new division is pursuing two broad initiatives which include identifying technology that it plans to develop or acquire in support of new projects related to an industrial security system and the chemical recycling of plastic into fuel. Additionally, as part of its entry into the industrial security market, GelStat plans to secure intellectual property that complements its engineering capabilities in an attempt to gain a competitive advantage. The Company also expects to secure contracts with several medium-tier security facilities in the southeastern U.S. and is looking to gain market share of these types of facilities in the near future.

08:32 EST TC Biopharm shifts focus to FDA clinical trials - TC BioPharm has taken steps to focus its clinical strategy on the planned future FDA trials for TCB-008 in AML as a monotherapy and other oncology indications in combination with additional assets. The pending protocol submission will be a Phase 1b safety trial, with a relatively small patient population and a short timeline to completion. The company intends to file the first IND in Q3 with an expected additional IND to be filed in Q4 or early 2024. At this juncture, the company is anticipating a dose escalating study of approximately 9 patients with an expansion cohort at the optimal dose. TC BioPharm expects this US clinical trial enrollment to be relatively rapid due to the the fact that America offers a significantly greater pool of patients with more than 20,000 AML diagnoses each year. This transition aims to allow TC BioPharm to become more economically efficient by simplifying its strategy and reducing manufacturing and production efforts.

08:31 EST iCoreConnect receives Nebraska Dental Association endorsement - iCoreConnect announced the Nebraska Dental Association's endorsement of iCoreConnect's cloud-based ePrescription software, iCoreRx.

08:27 EST Getty Images, Candy Digital partner for 1970s music icon collectibles - Candy Digital and Getty Images announced the partnership of Exposure: by Getty Images & Candy. For the first time, rare photographs from Getty Images' storied archives will be available to individual fans and collectors to own and collect as part of the '70s Music & Culture Collection. In celebration of the collaboration kickoff, Candy Digital will also offer photography and music fans the ability to mint an introductory image for free for a limited time. The '70s Music & Culture Collection contains digital collectible photographs that were meticulously curated by Getty Images experts and archivists to create a celebration of the iconic artists and moments that defined music and culture in the 1970s, as well as the photographers who captured them. Getty Images' digital archival collectibles on Candy.com showcase imagery captured by six of the most skilled photographers of their generation: Don Paulsen, David Redfern, Fin Costello, Richard Creamer, Steve Morley, and Peter Keegan. The collection is comprised of unique images captured by these photographers, including iconic works depicting Bruce Springsteen, Elvis, David Bowie, Stevie Nicks, Rolling Stones, Jimi Hendrix, AC/DC, Gladys Knight, James Brown, and John Lennon via open edition mint. The collection will be available starting on March 21st, ranging from $25 to $200 on Candy.com. Fans and collectors can process their transactions through credit card payments, an accessible on-ramp offering for the non-Web3 audience. Fans from the United States, Australia, Canada, France, Germany, Hong Kong, Japan, Portugal, Spain, United Kingdom can visit Getty Images Digital Collections page.

08:27 EST Indaptus Therapeutics doses first subject in ongoing Phase 1 lab - Indaptus Therapeutics announces the dosing of the first subject in INDP-D101. INDP-D101 is the Company's first-in-human, open label, dose escalation and expansion, multicenter Phase 1 clinical trial of its lead compound Decoy20 in patients with advanced/metastatic solid tumors. After Decoy20 dosing, the subject experienced expected and manageable adverse events believed to be related to the immune system activating components known to be in the product. A second subject in the first three-subject cohort is expected to be enrolled following final assessment of the safety and tolerability associated with dosing of the first subject, per the study protocol. The study's objectives are to assess the safety and tolerability of Decoy20, to determine the maximum tolerated dose and recommended phase 2 dose, as well as to assess Decoy20 pharmacokinetics, pharmacodynamics and clinical activity. The Phase 1 study was initiated with a single dose escalation, which is planned to be followed by an expansion with continuous weekly administration of Decoy20. The primary endpoint of the study is incidence, relatedness and severity of adverse events and treatment-emergent adverse events and determination of the number of subjects per cohort with dose limiting toxicity-based adverse events.

08:25 EST Qorvo expands power management portfolio - Qorvoexpanded its power management portfolio to include the PAC22140 and PAC25140 Power Application Controller devices. The two PACs are the industry's first single-chip solutions to offer support for battery packs with up to 20 cells in series. These products leverage an intelligent motor control foundation to enable intelligent battery management solutions for a wide range of industrial, e-mobility and battery backup applications.

08:23 EST Baker Hughes, HIF Global to collaborate on direct air capture technology - Baker Hughes announced Tuesday their agreement to cooperate on the development of technology to capture carbon dioxide directly from the atmosphere. More specifically, HIF Global and Baker Hughes intend to test Baker Hughes' Mosaic DAC technology pilot units to accelerate DAC deployment at commercial scale. "Collaboration is key to supporting and accelerating the energy transition to address climate change, and we are pleased to work alongside HIF to support their significant efforts in deploying eFuels at scale, leveraging our Mosaic DAC technology," said Lorenzo Simonelli, chairman and CEO of Baker Hughes. "This milestone agreement further illustrates the strength of Baker Hughes' extended portfolio of Climate Technology Solutions, which includes a variety of CCUS technologies, and validates our strategy and commitment toward decarbonization." Acquired by Baker Hughes in April 2022 to enhance its carbon capture, utilization and storage portfolio, Mosaic Materials is focused on developing a proprietary direct air capture technology using Metal-Organic Framework materials that can be used to separate CO2 from the atmosphere.

08:22 EST Freshworks expands leadership team, three new SVP - Freshworks (FRSH) announced the addition of three new senior vice presidents, SVP, to the go-to-market leadership team to capture demand for its multi-product SaaS solutions serving customer support, IT, marketing and sales teams. As companies seek greater value for their IT spend, Freshworks provides enterprise software for customer and employee facing teams that provide rapid impact and lasting value at a reasonable price. The new set of go-to-market leaders include SVP of GTM Strategy and Operations Shafiq Amarsi, SVP of Customer Experience Murali Krishnan, and SVP of Global Channels and Alliances Doug Farber. Shafiq Amarsi, senior vice president of go-to-market strategy and operations, will oversee sales and marketing operations, strategy and program management, sales enablement and IT. Shafiq spent the last 8 years at Amazon (AMZN) Web Services where he led the worldwide sales strategy, operations & enablement teams. Murali Krishnan, senior vice president of customer experience, will oversee customer support, onboarding and digital expansion. Krishnan was most recently working at Sprinklr. Shafiq and Murali join the executive leadership team reporting to Freshworks' CEO Girish Mathrubootham and to President Dennis Woodside along with Chief Marketing Officer Stacey Epstein, Chief Product Officer Prakash Ramamurthy, Chief Financial Officer Tyler Sloat, Chief Legal Officer Pam Sergeeff, Chief Human Resources Officer Suman Gopalan, and acting Chief Revenue Officer Pradeep Rathinam. Doug was most recently Vice President of Worldwide Channels and Alliances at Elastic (ESTC).

08:20 EST Salarius Pharmaceuticals to present in vitro data on seclidemstat - Salarius Pharmaceuticals announces that Justine Delgado, Ph.D., Research Manager, will be presenting a poster titled "Pre-clinical Investigation of the LSD1 Inhibitor, SP-2577 in Small Cell Lung Cancer" at the Keystone Symposia on Epigenetics, Chromatin, Development and Disease on March 13, 2023. The conference is being held March 12-15 at the Fairmont Express Victoria Conference Center in British Columbia. In an in vitro cell panel representing 13 diverse small cell lung cancer cell lines, seclidemstat demonstrated significant anti-proliferative single agent activity. To assess the potential for synergistic combination with the current treatment option for second-line SCLC - topotecan and the recently approved transcriptional inhibitor, Lurbinectedin - combination studies were performed in cell lines and revealed additive to synergistic activity in a subset of these cell lines. RNA-sequencing revealed SP-2577 impacted various known LSD1-regulated transcriptional programs, including NOTCH signaling and epithelial to mesenchymal transition.

08:18 EST ProPhase Labs' Nebula Genomics introduces lowest NGS pricing - ProPhase Labs announced that its wholly owned subsidiary, Nebula Genomics, has introduced its lowest ever standard price of $249.00 for its direct-to-consumer whole genome sequencing DNA test. "With limited competing products that offer standard pricing between $400-$1100, Nebula Genomics' new standard price is the most affordable in the United States for 30X WGS and further cements us as a leader in DTC WGS services," commented Ted Karkus, ProPhase Labs' Chief Executive Officer. "Our mission at Nebula is to usher in a new era of personal genomics by providing access to affordable and secure whole genome sequencing, and today's announcement marks strong progress toward this goal," continued Karkus. "It's our view that the future of health and wellness is personalized therapies based on each individual's genetic makeup, and our WGS services, now more accessible than ever, enables that future. We seek to harness the power of the entire human genome, while delivering as much value as possible to our customers."

08:16 EST Panbela announces first patient enrolled in ASPIRE trial on SBP-101 - Panbela Therapeutics announced its first patient enrolled in South Korea for its ASPIRE global clinical trial in the first-line treatment of metastatic pancreatic cancer. ASPIRE is a global randomized, double-blind placebo-controlled clinical trial to evaluate ivospemin in combination with gemcitabine and nab-Paclitaxel in patients with metastatic pancreatic ductal adenocarcinoma. "We're really excited to continue the Country and site initiation for the ASPIRE trial as we aim to have the full complement of sites on board by the middle of this year," said Jennifer K. Simpson, PhD, MSN, CRNP, President & Chief Executive Officer of Panbela. "Having South Korean enrollment underway is highly encouraging as we continue to ramp up the trial. We're targeting the interim analysis in early 2024."

08:16 EST Microchip announces industrial-grade SPE products - Microchip Technology announces new industrial-grade SPE products that will help fulfill SPE's promise, from 10BASE-T1S MAC-PHYs that more easily connect edge IIoT devices to the cloud, to industrial versions of its 100BASE-T1 Time Sensitive Networking Ethernet PHY transceivers and switches that enable higher-speed applications across far-reaching Ethernet networks.

08:14 EST DZS further expands Cloud EDGE portfolio with DZS Xtreme Transport - DZS has further expanded its Cloud EDGE portfolio with the launch of DZS Xtreme Transport. Along with the DZS Xtreme Access and DZS Xtreme Mobile solutions, DZS Xtreme Transport helps communications service providers accelerate deployment and streamline management of differentiating new services over next-generation, high-bandwidth and low-latency optical broadband infrastructure. The DZS Xtreme Transport solution will be highlighted at the Optical Fiber Communication Conference and Exhibition taking place in San Diego, March 7 - 9.

08:14 EST iKena Oncology presents preclinical data on IK-595 - Ikena Oncology announced that the Company is presenting preclinical data on its newest program in next-generation MEK-RAF inhibition, IK-595, at the American Association for Cancer Research, AACR, Special Conference: Targeting RAS, taking place this week in both a poster presentation and a plenary session talk. Highlights of the poster and Dr. Zhang's oral presentation include: IK-595 stabilizes the MEK-RAF complex in an inactive conformation to stop CRAF bypass; IK-595 potently blocks MEK phosphorylation in RAS mutant cancer cells; IK-595 achieves deeper and more durable inhibition of MAPK signaling and ERK phosphorylation across multiple KRAS mutant, NRAS mutant, and CRAF altered cancer cell lines, compared to existing MEK inhibitors; IK-595 drives robust anti-tumor efficacy and tumor regression in mouse models of KRAS mutant, NRAS mutant, and CRAF amplified cancers, across pancreatic, lung, bladder, and AML; Strong synergy of IK-595 in combination with therapies targeting multiple key mechanisms in vitro, including in combination with KRAS G12C, EGFR, PI3K, mTOR, SHP2, and SOS1 inhibitors; IK-595 is designed to have a shorter projected half-life in humans that allows a differentiated dosing strategy potentially achieving a greater therapeutic window than existing MEK inhibitors. Ikena plans to submit an Investigational New Drug application (IND) for IK-595 in the second half of 2023.

08:12 EST Ascent Solar to acquire certain assets of European manufacturer - Ascent Solar Technologies announced that it has signed a definitive term sheet to acquire certain manufacturing assets of a leading European manufacturer of thin-film solar technology and a worldwide license of its intellectual property portfolio, for $5M cash. The term sheet also provides that the Company will enter into an option to acquire a controlling interest in the manufacturer's industrial-scale manufacturing operations, subject to the satisfaction of certain conditions. The option would have an exercise price of $3 million, in addition to the conversion of certain outstanding liabilities at the time of exercise into ASTI stock, at a price of USD $2.00 per share. These transactions are expected to transform ASTI's operating fundamentals through added revenue and market segments, increased production capacity, and access to an expanded IP portfolio for R&D and licensing opportunities. Revenue: ASTI will service the European manufacturer's significant outstanding contracts using the acquired equipment, and expects to become the direct counterparty for the customers of the acquired assets on all upcoming contract renewals. Upon completion of the transaction, management anticipates EBITDA-positive operations of the acquired assets as early as the second half of 2023. Market Expansion: The transaction is expected to immediately provide ASTI with the opportunity and proven manufacturing capacity to establish new revenue streams in the luxury goods and building integrated photovoltaics markets. Advanced Manufacturing Facility: ASTI will acquire the European manufacturer's equipment at its modern 15MW plant, which is capable of providing production outputs of polymer web up to one meter in width and one kilometer in length and would deliver a 300% increase in nameplate manufacturing capacity to ASTI. Industrial-Scale Manufacturing Option: ASTI will acquire an option for a controlling interest in the European manufacturer, including its 40MW, thin-film CIGS facility which is optimized for high efficiency and high yields. Expanded IP Portfolio: ASTI will acquire a license to the European manufacturer's extensive IP portfolio. Under the terms of the term sheet, which was approved by a committee comprised of the independent and disinterested members of the board of directors of ASTI, ASTI will pay USD $5 million, in cash, subject to certain closing adjustments, for the acquired assets and the IP license. Following the closing, ASTI will have the option to acquire a controlling interest in the European manufacturer, for a cash price of USD $3 million, along with the repayment of certain liabilities in shares of ASTI stock, valued at a price of USD $2.00 per share. The transaction remains subject to the execution of definitive agreements on terms acceptable to the parties. Closing is targeted for early in the second quarter, subject to customary closing conditions.

08:11 EST Crescent Point Energy's normal course issuer bid approved by TSX - Crescent Point Energy announced that the Toronto Stock Exchange has accepted its notice to implement a normal course issuer bid to purchase, for cancellation, up to 54,605,659 common shares, or 10% of the company's public float, as at February 23. The NCIB is scheduled to commence on March 9, 2023 and is due to expire on March 8, 2024. Purchases of Crescent Point's common shares under the NCIB may be made through the facilities of the TSX, the NYSE and alternative trading systems by means of open market transactions or by such other means as may be permitted by the Canadian Securities Administrators and under applicable securities laws, including by private agreement pursuant to issuer bid exemption orders issued by applicable securities regulatory authorities. As of February 23, 2023, the Company had a public float of 546,056,596 common shares and 548,600,237 common shares issued and outstanding. Under its current NCIB that expires March 8, 2023, Crescent Point has repurchased an aggregate 28,733,300 common shares out of a permitted 57,309,975 common shares as at February 28, 2023 at a weighted average price of $9.62 per share.

08:10 EST ReWalk Robotics announces ReWalk Personal Exoskeleton receives FDA clearance - ReWalk Robotics announced that its innovative ReWalk Personal Exoskeleton technology has received clearance from the Food and Drug Administration, FDA, for use on stairs and curbs in the United States, making it the only personal exoskeleton to receive FDA clearance for this indication. The clearance follows the FDA's designation of the device as a "Breakthrough Device" in recognition of its unprecedented ability to provide ambulatory access to environments containing stairs and curbs for paralyzed individuals with spinal cord injury. "Our mission at ReWalk has been to achieve widespread access to the health benefits of walking in everyday life for individuals with spinal cord injury," said Larry Jasinski, CEO of ReWalk. "Today's announcement demonstrates our commitment from a technical perspective to improve access to a broader range of activities of daily living, such as walking up the steps to visit a friend's home, or stepping over a curb during a neighborhood walk. In parallel, our focus continues to be to broaden access to these life changing technologies through expanding payor coverage as we continue to work with Medicare to develop the pathway to reimbursement for medically-eligible individuals."

08:08 EST Oxford Lane estimates NAV per share $4.98-$5.08 as of February 28 - Management's unaudited estimate of the range of the NAV per share of our common stock as of February 28, 2023 is between $4.98 and $5.08. This estimate is not a comprehensive statement of our financial condition or results for the month ended February 28, 2023. This estimate did not undergo the Company's typical quarter-end financial closing procedures and was not approved by the Company's board of directors. We advise you that our NAV per share for the quarter ending March 31, 2023 may differ materially from this estimate, which is given only as of February 28, 2023. As of February 28, 2023, the Company had approximately 170.5 million shares of common stock issued and outstanding.

08:07 EST ShiftPixy enters partnership with Allied Sports - ShiftPixy announced it has selected Allied Sports as its agency of record for influencer marketing and brand partnerships aimed at promoting the new Digital Food Brands of ShiftPixy Labs.

08:06 EST WPP acquires German healthcare specialist 3K Communication, no terms - WPP announces that it has acquired 3K Agentur fur Kommunikation, 3K , "one of the leading healthcare specialist PR agencies in Germany," noted the company. 3K will become part of the Hill+Knowlton Strategies global network, strengthening its healthcare presence in Europe and expanding its operations in Germany. Founded 25 years ago, 3K is known for its expertise in healthcare, biopharmaceuticals, and related sciences, working with some of the world's most notable global pharmaceutical companies, consumer health brands, and local biotech start-ups. The addition of 3K aligns with WPP's strategic focus on healthcare and marks the company's continued investment in Germany. In the second half of 2022, WPP appointed Wendy Lund as Chief Client Officer for Health & Wellness and FM Schmidt as WPP's first President of the German market. The acquisition is also the latest milestone in H+K's ongoing transformation. The agency has grown more than 25% over the last two years, expanding its global leadership team - including Brenna Terry as Global Chair of Healthcare - and acquiring the JeffreyGroup in Latin America.

08:06 EST Novan announces FDA accepted NA for berdazimer gel, 10.3% - Novan announced that the U.S. Food and Drug Administration, FDA, accepted for filing Novan's New Drug Application, NDA, seeking approval for berdazimer gel, 10.3% for the treatment of molluscum contagiosum. The Company also received its Prescription Drug User Fee, PDUFA, goal date of January 5, 2024. "The opportunity for our NDA to be approved in less than 10 months from today marks a significant and important milestone for Novan and its shareholders. We believe our NCE can provide a much-needed therapeutic option for molluscum patients with the added benefit of being an easily applied, topical, self-administered treatment," commented Paula Brown Stafford, President and Chief Executive Officer of Novan. "We are thrilled that the FDA determined our application is sufficiently complete, no filing review issues were identified, and that the substantive review process has commenced."

08:04 EST Steakholder Foods restructures Peace of Meat for cultivated avian product - Steakholder Foods announces a restructuring plan for Peace of Meat - PoM - aimed at supporting the submission of a cultivated avian food product for regulatory approval in Singapore, the first, and so far, only country that has completed the approvals process for the consumption of cultivated meat. As part of this plan, the company will be implementing a series of changes designed to streamline its operations and position it for success. As part of PoM's new business plan for 2023, the company will focus on regulatory submissions for its avian product - finalizing a submission to the Singapore Food Agency by the end of 2023, and preparing for submission in the USA. PoM intends to scale up production through a third-party plant, allowing for a cost-effective and accelerated process and eliminating the need to continue advancing its more resource-intensive pilot plant project. The new, efficient structure will allow faster development and will involve targeted layoffs in areas of the business that are not directly related to the regulatory submissions. This will enable the company to reduce overhead costs and allocate resources more effectively to support this important initiative.

07:58 EST Hanesbrands and UCLA announce multi-year apparel agreement, no terms - HanesBrands and UCLA announced a multi-year apparel agreement that gives HBI exclusive rights to design, manufacture and distribute high-quality, on-trend Bruins fanwear in the mass retail channel. HBI will develop exclusive collections featuring men's, women's, unisex, youth, infant and toddler fan apparel. The agreement starts in 2024, ahead of the school's highly anticipated move to the Big Ten Conference, where it will compete to extend its record-breaking 120 NCAA team national championships.

07:51 EST Arch Therapeutics expands contracted sales force for AC5 system - Arch Therapeutics announced an expansion of its contracted sales force with a dedicated team of independent representatives whose primary objective will be to support surgeons and other medical professionals as well as advance the commercialization of AC5 Advanced Wound System in high volume government facilities. The Company is on schedule to add approximately fifteen independent commission-based sales representatives by the end of Q1 2023 dedicated to supporting AC5, Arch's self-assembling wound care product, in federal government agencies, including the Department of Veterans Affairs, Indian Health Services, Department of Defense and Medical Treatment Facilities. These additional representatives will be deployed to optimize opportunities in newly created sales regions and in current regions that have had initial and restocking orders for AC5.

07:47 EST Electric Royalties provides update on Authier Lithium Royalty - Electric Royalties announced that Sayona Mining has voluntarily submitted its Authier Lithium Project for an environmental impact assessment and review under the Quebec Government's 'BAPE' process. According to Sayona's news release dated February 27, 2023, its request has been accepted by Quebec's Ministry of the Environment, the Fight Against Climate Change, Wildlife and Parks. The BAPE's mission is assist government decision-making by communicating to the environment minister findings and opinions that reflect any local concerns that are based on the principles of the Sustainable Development Act. Sayona also reported that its nearby North American Lithium operation in Quebec, Canada, is on track to recommence spodumene production in March 2023. The start-up of process operation was reportedly successful, and comprises the circulation of mineralized material through the entire system, from crushing through sorting, grinding and separation. Authier is envisioned by Sayona to become a source of spodumene feed for the NAL concentrator. As a result, the Authier Project no longer requires its own concentrator or tailings storage, and the planned daily output below the 2,000-tonne threshold has resulted in a considerably reduced environmental impact compared to the original regulatory submission. Electric Royalties holds a 0.5% gross metal royalty on the Authier Lithium Project.

07:40 EST Nextech AR Solutions rebrands to Nextech3D.ai - Nextech AR Solutions Corp. has rebranded to better reflect its current technology and business. As previously reported, the Company believes that its generative AI has given it a competitive edge and is driving the Company toward becoming cash-flow positive. The Company's CTO Nima Shasar has significantly expanded his team with three new full-time AI scientists to bolster its AI development and keep pace with its ambitious AI growth plans for 2023. The Company's portfolio of new brands are: Nextech3D.ai; Arway.ai; Toggle3D.ai. Nextech3D.ai CEO Evan Gappelberg comments, "We have been able to create incredibly powerful artificial intelligence that really changes the game, between what we have been able to produce with a human versus, what's happening now with our generative AI-Powered 3D model factory." He continues, "We effectively have transitioned from a diversified Augmented Reality Company and pioneering metaverse Company to an leading AI-powered 3D modeling for e-commerce company. We believe that we have a competitive advantage in the $ 100 billion TAM 3D market and that anyone in our industry that doesn't embrace the disruptive power of generative AI will find themselves at an enormous and insurmountable disadvantage from both a cost and innovation perspective." The Company has affected the business name registration of Nextech3D.ai with the applicable corp. regulatory authorities, the stock symbols will remain the same.

07:38 EST ARway files provisional patent for digital twin technology - ARway Corporation has filed the first in a series of patents around its technology. The provisional utility patent titled "System & method for generating 3D digital twins from property floorplan images for Augmented Reality systems," was filed with the United States Patent and Trademark Office and is a crucial step in advancing ARway's digital twin technology. This disruptive technology eliminates the complexity and expense of creating digital environments with hardware like BLE beacons, Ultra Wide Band, satellite technology as well as laser and LiDAR scanners.

07:36 EST Terreno Realty acquires property in Queens, NY for $23M - Terreno Realty acquired an industrial property located in Long Island City, Queens, New York on March 6 for a purchase price of approximately $23M. The property consists of one industrial distribution building containing approximately 45,000 square feet on 1.1 acres. The property is at 42-11 9th Street, immediately adjacent to the Queensboro 59th Street Bridge connecting Manhattan and Queens, provides one dock-high and two grade-level loading positions and off-street parking for 13 cars. The property is 100% leased on a short-term basis and the estimated stabilized cap rate is 5.2%. Estimated stabilized cap rates are calculated as annualized cash basis net operating income stabilized to market occupancy divided by total acquisition cost. Total acquisition cost includes the initial purchase price, the effects of marking assumed debt to market, buyer's due diligence and closing costs, estimated near-term capital expenditures and leasing costs necessary to achieve stabilization.

07:36 EST Small Pharma announces further data from SPL026 Phase II trial - Small Pharma announces further results from the Company's Phase IIa trial of SPL026, the first placebo-controlled study of a short-duration psychedelic for the treatment of Major Depressive Disorder. The trial investigated the efficacy and safety of a 21.5mg intravenous dose of SPL026, N,N-Dimethyltryptamine, with supportive therapy in 34 patients with moderate/severe MDD. Analyses of additional secondary and exploratory endpoints, including effects on self-reported depression, anxiety and wellbeing, demonstrated that patients receiving at least a single dose of IV SPL026 with supportive therapy experienced clinically relevant improvements in function and mood, further supporting previously announced topline efficacy results. The two-staged study included a two-week blinded, randomized, placebo-controlled phase followed by a 12-week open-label phase, in which all participants received a single dose of SPL026. In January 2023 the Company reported that the Phase IIa trial met its primary endpoint with a statistically significant and clinically relevant reduction in depression symptoms at two-weeks post-dose, compared to placebo. SPL026 with supportive therapy also demonstrated a rapid onset and durable antidepressant effect, as assessed by the Montgomery-Asberg Depression Rating Scale. Analysis of patient-reported depression scores corroborate the MADRS assessments conducted by independent clinical raters. Improvements in depression scores from baseline were observed across all study timepoints in patients receiving at least a single dose of SPL026, as measured by the Beck Depression Inventory, including a statistically significant improvement in depression symptoms compared to placebo at two-weeks post-dose. The efficacy outcomes on the BDI were consistent with MADRS, providing additional support for the rapid and sustained therapeutic profile of SPL026 for the treatment of MDD. Measures assessing patients' anxiety and wellbeing, areas which are often negatively impacted by depression, were also analyzed across the study. Following both one and two doses of IV SPL026 with supportive therapy, patients demonstrated a rapid and sustained improvement in anxiety symptoms as measured by the State-Trait Anxiety Inventory-Trait scale. A statistically significant improvement in anxiety symptoms was observed compared to placebo at two-weeks post-dose. At 12-weeks following the open-label dose, a -14.2 mean change from baseline was demonstrated in the patient group receiving the single dose regimen. Further, a rapid and sustained improvement in wellbeing was observed following at least a single treatment of IV SPL026 with supportive therapy, as measured by the Warwick-Edinburgh Mental Wellbeing Scale. The results at two-weeks following the blinded dose of SPL026 or placebo showed a 10.1 mean CFB in the SPL026 group compared to 0.9 in the placebo group. Statistical analysis was conducted on the MADRS open-label data. A statistically significant difference in mean total MADRS score was observed for both the one and two dose regimen groups across all open-label study timepoints. Further analysis was conducted to assess the difference in total MADRS scores between the one and two dose regimen groups using a mixed model of repeated measures for all subjects across all timepoints. No statistical difference was demonstrated between these dose regimens across all time points to 12-weeks. This analysis provides further support that a single dose of SPL026 is sufficient to elicit a rapid and durable antidepressant effect.

07:35 EST Starbox's cash rebates system enters Philippines market - Starbox Group announced its Malaysian subsidiary, Starbox Rebates Sdn. Bhd., has entered into a Private Label Cash Rebates System Supply Agreement with MY Rebates PH Solutions Corporation, MYRPHSC, an entity incorporated in the Philippines. The Company believes that MYRPHSC possesses the necessary resources and capabilities to sustain the development and growth of the Company's cash rebate system in the Philippines. The Private Label Cash Rebates System Supply Agreement stipulates that MYRPHSC, as the Company's exclusive partner in the Philippines, shall utilize the cash rebate system, digital advertising and related attributes of Starbox Group therein to promote and develop the Company's services in the Philippines. Lee Choon Wooi, Chief Executive Officer and Chairman of the Board of Directors of Starbox Group, commented, "The Philippines is the first overseas market for our cash rebate system, and our technical team will provide the system with vigorous assistance. We are confident that the Philippines will be a stimulating prospect for the expansion of Starbox Group and we aspire to expand our reach to more South East Asian countries in the future."

07:33 EST DraftKings set to launch online sportsbook in Massachusetts - DraftKings announced plans to launch its top-rated online sportsbook in Massachusetts on March 10, 2023, pending licensure and receipt of regulatory approvals. Upon launch, Massachusetts will become the 21st U.S. state in which Boston-based DraftKings offers its online sportsbook. Beginning March 10, eligible customers in Massachusetts will have the opportunity to place bets on DraftKings Sportsbook across numerous sports and teams. "It was just over 10 years ago when we launched DraftKings from a spare bedroom in Watertown, and now, we are proud to have the opportunity to deliver a safe and legal sports betting product to millions of diehard sports fans across Massachusetts," said Jason Robins, DraftKings' co-founder, Chief Executive Officer and Chairman. "This launch will mark a major milestone for our company, and we're proud to become the hometown sportsbook for customers in the Commonwealth."

07:31 EST NeuroOne Medical awarded U.S. patent relating to electrode technology - NeuroOne Medical announces it has been awarded a patent from the United States Patent and Trademark Office relating to its novel and proprietary electrode technology. The patent, titled "Improved Neural Depth Probes and Related Systems and Methods," adds to NeuroOne's intellectual property portfolio, and is focused on a layered thin film neural depth electrode. The electrode could have potential applications in a wide variety of neurological procedures for both diagnostic and therapeutic use. Conditions that could potentially benefit from this technology include epilepsy, Parkinson's disease, chronic back pain due to failed back surgeries, and mood- based disorders associated with depression, severe OCD, etc.

07:23 EST Tilray's SweetWater Brewing Company introduces Gone Trippin' IPA - SweetWater Brewing Company announces the launch of Gone Trippin', a West Coast Style India Pale Ale that pays tribute to the bold, hoppy beers SweetWater brought to the South more than 25 years ago. Gone Trippin' is now available nationally year-round on draft and in 6-packs and 12-packs of 12-ounce cans. Gone Trippin' is now flowing at SweetWater's flagship taprooms in Atlanta and Fort Collins, Colorado. It's also available in cans across Colorado, Georgia, Minnesota, Mississippi, North Carolina, South Carolina, Tennessee and Virginia at select retailers, including Total Wine & More, Kroger, Harris Teeter, Ingles, Publix, and Lowes Food. Distribution will expand to additional states later this year.

07:19 EST Magna announces launch of SmartAccess power door system - Magna announces the launch of its SmartAccess power door system on the opposing rear doors of the Ferrari Purosangue. The complete system includes Magna's power door drive unit, SmartLatch with cinch actuator and first-to-market integrated Haptronik software. "As an industry leader in advanced mechatronic systems, we are excited to bring one of our most innovative solutions to market," said Jeff Hunt, President of Magna Mechatronics, Mirrors and Lighting. "By combining our mechanical expertise with our advanced software capabilities, we have been able to reimagine traditional vehicle access and offer a unique and more luxurious experience when entering the Purosangue." The system will launch with several other Asian and North American automakers in 2023.

07:18 EST Tonix Pharmaceuticals announces results from preclinical study of mTNX-1700 - Tonix Pharmaceuticals announced that preclinical results of mTNX-1700 were presented in a poster at the Keystone Symposia, "Cancer Immunotherapy: Mechanisms of Response Versus Resistance" on March 6, 2023, at the Fairmont Banff Springs Conference Center in Banff, Alberta, Canada. The poster, titled "TFF2-MSA Suppresses Tumor Growth and Increases Survival in an anti-PD-1 Treated MC38 Colorectal Cancer Model by Targeting MDSCs," includes data from preclinical studies which evaluated the ability of mTNX-1700 to treat colorectal cancer as monotherapy or in combination with anti-PD-1 in mouse models. TNX-1700 targets myeloid-derived suppressor cells which interfere with the immune response to cancer by suppressing the CD8+ T cell response and creating a toxic tumor microenvironment. The data show that mTNX-1700 and anti-PD-1 monotherapy each were able to evoke anti-tumor immunity in the MC38 model of colorectal cancer, and that mTNX-1700 augmented the anti-tumor efficacy of anti-PD-1 therapy in two different colorectal cancer models. "Anti-PD-1 treatment has revolutionized the treatment of other cancers and is known as immuno-oncology," said Seth Lederman, M.D., Chief Executive Officer of Tonix. "Colorectal cancer is notoriously unresponsive to anti-PD-1 treatment. Much research has been focused on trying to turn anti-PD-1 unresponsive tumors into anti-PD-1 responsive tumors."

07:16 EST Optinose sees 2023 operating expenses $90M-$95M - The Company has prioritized the potential launch of XHANCE as a treatment for chronic sinusitis and will reduce total GAAP operating expenses for full year 2023 compared to full year 2022 by approximately $30.0 million or 25%. Approximately half of the $30.0 million reduction is attributable to sales and marketing and the remainder is attributable to reduced research and development, and general and administrative expenses. As part of actions intended to reduce total operating expenses for full year 2023 the Company reduced its number of territory managers by approximately 15% at the end of 2022. As a result of these actions, the Company expects total GAAP operating expenses for 2023 to be in the range of $90.0 to $95.0 million, of which the Company expects stock-based compensation to be approximately $8.0 million

07:15 EST Procept BioRobotics announces Aquablation Therapy received MIB from NICE - PROCEPT BioRobotics Corporation announced Aquablation Therapy received a MedTech Innovation Briefing, MIB, from the National Institute for Health Care Excellence, NICE, for benign prostate hyperplasia in the United Kingdom. NICE has recognized Aquablation Therapy is as effective as transurethral resection of the prostate, TURP, for the removal of prostate tissue for men with BPH. A panel of clinical experts said the technology is innovative compared to the standard of care and offers additional benefits, such as increased ability to preserve sexual function. "The NICE MedTech Innovation Briefing further validates the value we believe Aquablation Therapy brings to patients, doctors, hospitals and healthcare systems around the world," said Sham Shiblaq, Executive Vice President, Chief Commercial Officer of PROCEPT(R) BioRobotics. "The robust body of clinical evidence shows Aquablation therapy offers improved safety and durability when compared to transurethral resection of the prostate, which is the current gold standard surgical treatment option."

07:15 EST Rocket Lab schedules next Electron launch from Virginia - Rocket Lab announced it has scheduled its next Electron launch from Virginia during a launch window that opens March 11. The "Stronger Together" mission is scheduled to launch from Rocket Lab Launch Complex 2, or LC-2, on Wallops Island, Virginia for American space tech company Capella Space, a leading provider of commercial Synthetic Aperture Radar, or SAR, imagery. The mission will be Rocket Lab's second launch from the Mid-Atlantic Regional Spaceport at NASA's Wallops Flight Facility following from the company's inaugural mission from LC-2 on January 24.

07:11 EST Pacific Biosciences begins commercial shipment of Revio sequencing systems - Pacific Biosciences announced the first customer shipments of Revio long-read sequencing systems will commence on March 8. The Revio system features advances in SMRT Cell design, compute, and system architecture. With the Revio system, researchers will be able to scale their interrogation of the full genome in the same run. The Broad Institute of MIT and Harvard has ordered ten Revio systems to scale long-read sequencing for population sequencing initiatives. Additional Revio systems will also be shipped to customers in China, Japan, Korea, Netherlands, and Sweden. PacBio announced orders of 76 Revio systems in the quarter ended December 31, 2022. PacBio expects to ship at least 25 Revio systems during Q1 and will continue to scale throughout the year.

07:09 EST Achilles Therapeutics expects cash to fund operations into middle of 2025 - Cash and cash equivalents were $173.3 million as of December 31, 2022, as compared to $266.3 million as of December 31, 2021. With increased focus on the ongoing Phase I/IIa CHIRON and THETIS clinical trials and deprioritization of non-core activities, the Company anticipates that its cash and cash equivalents are sufficient to fund its planned operations into the middle of 2025. The decrease in cash and cash equivalents in 2022 reflects an underlying use of $67.1 million for operating activities and purchases of property and equipment, as well as a $25.9 million foreign exchange effect as the Company retranslates cash and cash equivalents at the prevailing U.S. dollar period rate. The Company's functional currency and underlying cash and cash equivalents are mainly held in British pounds sterling and translated into U.S. dollars for financial reporting.

07:06 EST Uber Eats partners with Tampa International Airport for mobile ordering - Uber Technologies announced a new partnership with Tampa International Airport, bringing mobile ordering to the airport's more than 21 million visitors and workers each year. Tampa Airport International Airport is Uber's first official US airport partner, after the Toronto Pearson Airport and pilots at John Glenn International Airport and Charlotte Douglas International Airport. With this expansion, consumers will be able to order ahead and skip the line at more than 20 concession locations.

07:04 EST Dick's Sporting sees FY23 CapEx $670M-$720M on gross basis - Sees FY23 CapEx $550M-$600M on a net basis.

07:03 EST Dick's Sporting raises annualized dividend to $4.00 per share - On March 6, the company's Board of Directors authorized and declared a quarterly dividend in the amount of $1.00 per share on the company's Common Stock and Class B Common Stock. The dividend is payable in cash on March 31 to stockholders of record at the close of business on March 17. This dividend represents an increase of 105% over the company's previous quarterly per share amount and is equivalent to an annualized dividend of $4.00 per share.

06:57 EST Dollar General reformulates, rebrands pet food line, Nature's Menu - Dollar General has reformulated and rebranded its dog and cat food line, Nature's Menu. The company's continued investment in private brands is illustrated through this elevated, now premium brand pet food at a value price, which was developed in response to consumer insights. This summer, Nature's Menu will debut a newly reformulated wet pet food, made in the U.S.A.

06:50 EST KKR sells four Class A self-storage properties for $80M - KKR announced that KKR has sold four Class A self-storage properties totaling approximately 2,897 units for approximately $80M. Two of the properties are located in Austin, TX and the other two are located in Phoenix, AZ and Riverside, CA. The properties were owned by KKR's Americas opportunistic equity real estate fund, KKR Real Estate Partners Americas III, and were sold in two separate transactions with different buyers.

06:36 EST Hut 8 Mining mines 156 Bitcoin in February - Hut 8 Mining mined 156 Bitcoin in the period ending February 28. In total, 156 Bitcoin were generated, resulting in an average production rate of approximately 5.6 Bitcoin per day.

06:34 EST ViewRay announces Czech Ministry of Health approval of MRIdian purchase - ViewRay announced the Czech Ministry of Health has approved the purchase of ViewRay's MRIdian system to bring advanced MRI-guided radiation therapy to treat its cancer patients at the Military University Hospital Prague in the Czech Republic. This is the first and only hospital to offer the precision of MRIdian Stereotactic MRI-guided Adaptive Radiotherapy, or SMART, in the Czech Republic. The purchase was co-financed by the REACT-EU financial instrument and the founder's contribution, the Ministry of Defense of the Czech Republic.

06:11 EST Theratechnologies receives Nasdaq non-compliance notification letter - Theratechnologies received a notification letter from Nasdaq advising that the company was not in compliance with listing rules because the bid price of the company's listed securities had closed at less than $1.00 per share over the last 30 consecutive business days from January 19 to March 2. The company has a period of 180 calendar days from the date of the Notification Letter, until August 30, to regain compliance with the Minimum Bid Price Requirement. The Nasdaq letter does not affect day-to-day trading and does not result in the delisting of the company's Shares. Theratechnologies shares are also listed on the Toronto Stock Exchange, and the Nasdaq Notification Letter does not affect the company's compliance status with that listing. If the company does not regain compliance by the end of the Compliance Period, the company may be eligible for an additional 180 calendar day period to regain compliance. The company intends to continue actively monitoring the bid price for its zhares between now and the expiration of the Compliance Period and will consider all available options to resolve the deficiency with every intention to regain compliance.

06:05 EST Opthea receives $6.3M R&D tax credit - Opthea announced that it has received a $6.3M research and development tax credit from the Australian Taxation Office. The cash incentive is for research and development costs incurred in the 2021/2022 financial year, and represents the amount disclosed in the company's audited financial statements at 30 June 2022.

06:03 EST Dole seeing 'improvements in global supply chains' - The company said, "The operating environment in 2023 continues to bring both new opportunities and new challenges. We are continuing to see improvements in global supply chains and signs of moderating inflation, which can have a positive impact on our business. However, we have also witnessed further weather events, such as colder weather in Spain and Northern Africa, which have created challenges for importers in Northern Europe at the start of the year. Within our own business, we recently experienced a cybersecurity incident identified as ransomware. We moved quickly to contain the threat and have been working closely with leading cybersecurity experts to remediate the issue and secure our systems. We have also been cooperating with law enforcement. The incident had a limited overall impact on our operations; however, it was disruptive for our Chilean and Fresh Vegetables businesses in particular. Overall, for full year 2023, we believe our business is well positioned for growth. While forecasting in the current environment is complex, we are targeting full year Adjusted EBITDA of $350.0 million. This target assumes no contribution from the Fresh Vegetables division."

05:29 EST Consolidated Edison enters $1B accelerated share repurchase agreements - Consolidated Edison announced that it has entered into accelerated share repurchase agreements with two dealers to repurchase $1B in aggregate of its common shares. Con Edison is funding the repurchases under the accelerated share repurchase agreements from a portion of the proceeds from the sale of Con Edison Clean Energy Businesses, Inc. Under the terms of the accelerated share repurchase agreements, Con Edison will make payments of $1B in aggregate to the dealers on March 7 and will receive approximately 8.7M shares of Con Edison common shares in aggregate on the same day. The final number of Con Edison common shares to be repurchased from the dealers will be based on the volume-weighted average share price of Con Edison's common shares during the term of the applicable transaction, less a discount. The final settlement of the transactions under the accelerated share repurchase agreements is expected to occur no later than the third quarter of 2023.

05:20 EST Nokia announces Converged Charging solution selected by Hrvatski Telekom - Nokia announced that its Converged Charging software solution has been selected by Hrvatski Telekom to help the Croatian operator modernize on-line charging and better harness network monetization opportunities that can unlock new revenue streams. The deal expands Nokia's partnership with Hrvatski Telekom, which already uses a variety of other Nokia products, including its Voice Core and other software applications. As a containerized, microservices-based solution, Nokia Converged Charging, or NCC, will provide real-time rating and charging of voice, data, and SMS/MMS services used by Hrvatski Telekom prepaid and postpaid subscribers. NCC uses a charging configurator that utilizes an intuitive business user interface to quickly create new pricing and market offers, reducing the time required to on-board new customers and tap new commercial opportunities.

05:15 EST Tidewater to purchase 37 platform supply vessels from SOFF for $577M - Tidewater announced a definitive agreement to purchase 37 of Solstad Offshore ASA's, or SOFF, platform supply vessels, or PSV, for $577M. The addition of 37 PSVs makes Tidewater the largest owner and operator of high-specification PSVs, which is the OSV vessel class that has demonstrated the highest utilization through all market cycles. Tidewater intends to fund the transaction through a combination of new debt and cash on hand. The company has received commitments from a group of financial institutions, led by the company's existing lender DNB Bank ASA, for a three-year senior secured credit facility of up to $325M, and expects to raise new debt prior to closing of the Transaction. Closing of the transaction is subject to customary regulatory approvals and includes a financing contingency. The closing of such financing is subject to agreement on satisfactory documentation and the negotiation and satisfaction of customary conditions precedent. The transaction was unanimously approved by Tidewater's board of directors and is expected to close in the second quarter of 2023.